PriceTargets.com logo

BridgeBio Pharma - BBIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $74.37
  • Forecasted Upside: -0.52%
  • Number of Analysts: 21
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 20 Buy Ratings
  • 0 Strong Buy Ratings
$74.76 As of 12/4/2025 05:00 PM ET
▲ +0.61 (0.82%)

This chart shows the closing price for BBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BridgeBio Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBIO

Analyst Price Target is $74.37
▼ -0.52% Downside Potential
This price target is based on 21 analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $74.37, with a high forecast of $110.00 and a low forecast of $49.00. The average price target represents a -0.52% upside from the last price of $74.76.

This chart shows the closing price for BBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 21 contributing investment analysts is to moderate buy stock in BridgeBio Pharma. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 20 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 20 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 20 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$76.00 ➝ $84.00
11/7/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$76.00 ➝ $77.00
11/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$90.00
10/30/2025CowenReiterated RatingPositive ➝ Positive
10/30/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$55.00 ➝ $100.00
10/30/2025TD CowenBoost TargetBuy ➝ Buy$60.00 ➝ $95.00
10/30/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$69.00 ➝ $71.00
10/30/2025Piper SandlerBoost TargetOverweight ➝ Overweight$93.00 ➝ $98.00
10/30/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$100.00 ➝ $110.00
10/30/2025Truist FinancialReiterated RatingBuy ➝ Buy$66.00 ➝ $80.00
10/27/2025Leerink PartnersSet TargetOutperform ➝ Outperform$68.00
10/27/2025Evercore ISIReiterated RatingOutperform ➝ Outperform
10/27/2025HC WainwrightBoost TargetBuy ➝ Buy$70.00 ➝ $80.00
10/21/2025Raymond James FinancialBoost TargetOutperform ➝ Outperform$56.00 ➝ $59.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$70.00
9/12/2025UBS GroupBoost TargetBuy ➝ Buy$72.00 ➝ $82.00
9/3/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$55.00 ➝ $70.00
8/29/2025HC WainwrightBoost TargetBuy ➝ Buy$56.00 ➝ $70.00
8/6/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $57.00
8/6/2025OppenheimerBoost TargetOutperform ➝ Outperform$60.00 ➝ $61.00
7/30/2025Raymond James FinancialInitiated CoverageOutperform$56.00
7/29/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$95.00
7/21/2025Truist FinancialInitiated CoverageBuy$66.00
7/14/2025Piper SandlerBoost TargetOverweight ➝ Overweight$63.00 ➝ $68.00
7/14/2025Jefferies Financial GroupInitiated CoverageBuy$70.00
7/11/2025CitigroupBoost TargetBuy ➝ Buy$58.00 ➝ $67.00
7/9/2025OppenheimerUpgradeMarket Perform ➝ Outperform$60.00
6/30/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$67.00 ➝ $76.00
6/25/2025Bank of AmericaBoost TargetBuy ➝ Buy$50.00 ➝ $54.00
6/17/2025Wolfe ResearchInitiated CoverageOutperform$49.00
6/9/2025HC WainwrightBoost TargetBuy ➝ Buy$53.00 ➝ $56.00
4/30/2025Piper SandlerBoost TargetOverweight ➝ Overweight$46.00 ➝ $63.00
4/30/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.00
4/30/2025UBS GroupBoost TargetBuy ➝ Buy$65.00 ➝ $72.00
4/15/2025HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $53.00
3/31/2025Redburn AtlanticInitiated CoverageBuy$50.00
3/24/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$44.00 ➝ $50.00
2/21/2025CitigroupBoost TargetBuy ➝ Buy$45.00 ➝ $49.00
2/21/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$95.00 ➝ $95.00
2/21/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$49.00 ➝ $52.00
2/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
2/12/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$48.00 ➝ $49.00
12/23/2024Evercore ISIBoost TargetOutperform ➝ Outperform$45.00 ➝ $50.00
12/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
11/25/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$45.00 ➝ $48.00
11/25/2024Bank of AmericaBoost TargetBuy ➝ Buy$42.00 ➝ $45.00
11/25/2024HC WainwrightBoost TargetBuy ➝ Buy$43.00 ➝ $49.00
11/15/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $45.00
10/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
10/17/2024Leerink PartnersLower TargetOutperform ➝ Outperform$47.00 ➝ $46.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$44.00
10/3/2024OppenheimerInitiated CoverageMarket Perform
9/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $70.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
9/11/2024Bank of AmericaReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $70.00
9/4/2024Piper SandlerInitiated CoverageOverweight$46.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
8/7/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$46.00 ➝ $43.00
8/7/2024Evercore ISILower TargetOutperform ➝ Outperform$50.00 ➝ $45.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $70.00
6/25/2024Bank of AmericaLower TargetBuy ➝ Buy$50.00 ➝ $42.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
5/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $70.00
5/28/2024UBS GroupLower TargetBuy ➝ Buy$51.00 ➝ $47.00
5/20/2024HC WainwrightLower TargetBuy ➝ Buy$47.00 ➝ $43.00
5/14/2024Evercore ISIInitiated CoverageOutperform$50.00
5/13/2024Evercore ISIUpgradeStrong-Buy
3/21/2024Raymond James FinancialInitiated CoverageOutperform$45.00
3/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$35.00 ➝ $45.00
3/19/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$60.00 ➝ $70.00
3/5/2024MizuhoLower TargetBuy ➝ Buy$60.00 ➝ $53.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$47.00
2/23/2024CitigroupBoost TargetBuy ➝ Buy$42.00 ➝ $46.00
1/31/2024BMO Capital MarketsInitiated CoverageMarket Perform$37.00
1/29/2024HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $47.00
1/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$58.00
11/7/2023CitigroupInitiated CoverageBuy$42.00
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$50.00
8/28/2023MizuhoReiterated RatingBuy ➝ Buy$60.00
8/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$42.00 ➝ $38.00
8/14/2023MizuhoBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
7/18/2023The Goldman Sachs GroupBoost TargetBuy$29.00 ➝ $50.00
7/18/2023Raymond James FinancialBoost TargetOutperform$29.00 ➝ $46.00
7/18/2023BTIG ResearchBoost Target$32.00 ➝ $42.00
7/18/2023MizuhoBoost Target$29.00 ➝ $50.00
7/17/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$24.00 ➝ $33.00
5/8/2023MizuhoBoost Target$23.00 ➝ $29.00
4/19/2023Evercore ISIInitiated CoverageOutperform$40.00
4/13/2023SVB SecuritiesBoost TargetOutperform$25.00 ➝ $27.00
3/7/2023Raymond James FinancialBoost TargetOutperform$17.00 ➝ $29.00
3/7/2023The Goldman Sachs GroupBoost TargetBuy$20.00 ➝ $28.00
3/7/2023JPMorgan Chase & Co.Boost TargetOverweight$18.00 ➝ $23.00
3/7/2023Bank of AmericaBoost Target$15.00 ➝ $18.00
2/6/2023CowenInitiated CoverageOutperform
2/6/2023CowenInitiated CoverageOutperform
1/23/2023Leerink PartnersLower TargetOutperform$23.00 ➝ $19.00
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$20.00 ➝ $19.00
8/24/2022MizuhoLower TargetBuy$25.00 ➝ $23.00
7/26/2022Leerink PartnersBoost TargetOutperform$27.00 ➝ $30.00
6/15/2022The Goldman Sachs GroupBoost TargetBuy ➝ Buy$19.00 ➝ $21.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$24.00 ➝ $19.00
3/16/2022HC WainwrightLower TargetBuy$24.00 ➝ $22.00
3/11/2022JPMorgan Chase & Co.Lower TargetOverweight$21.00 ➝ $18.00
3/4/2022Leerink PartnersBoost TargetOutperform$24.00 ➝ $25.00
1/31/2022HC WainwrightReiterated RatingBuy$24.00
12/28/2021HC WainwrightLower TargetBuy$88.00 ➝ $24.00
12/27/2021Leerink PartnersLower TargetOutperform$66.00 ➝ $24.00
12/27/2021MizuhoLower TargetBuy$86.00 ➝ $25.00
11/19/2021Leerink PartnersLower TargetOutperform$68.00 ➝ $66.00
11/3/2021MizuhoReiterated RatingBuy
10/25/2021HC WainwrightReiterated RatingBuy
10/13/2021MizuhoInitiated CoverageBuy$86.00
10/4/2021Leerink PartnersBoost TargetOutperform$66.00 ➝ $68.00
9/10/2021Bank of AmericaUpgradeNeutral ➝ Buy$75.00
8/6/2021Leerink PartnersLower TargetOutperform$71.00 ➝ $66.00
7/16/2021Leerink PartnersReiterated RatingOutperform
5/20/2021UBS GroupInitiated CoverageBuy$80.00
5/7/2021The Goldman Sachs GroupLower TargetBuy$92.00 ➝ $80.00
4/11/2021Leerink PartnersReiterated RatingBuy
3/23/2021Jefferies Financial GroupReiterated RatingBuy$79.00
3/23/2021Leerink PartnersBoost TargetOutperform$67.00 ➝ $75.00
3/22/2021The Goldman Sachs GroupBoost TargetPositive ➝ Buy$83.00 ➝ $91.00
3/20/2021MizuhoInitiated CoverageBuy$86.00
3/4/2021MizuhoBoost TargetBuy$56.00 ➝ $86.00
2/22/2021JPMorgan Chase & Co.Initiated CoverageOverweight
2/9/2021The Goldman Sachs GroupReiterated RatingBuy$83.00 ➝ $83.00
1/11/2021HC WainwrightBoost TargetBuy$64.00 ➝ $87.00
12/14/2020BTIG ResearchBoost TargetBuy$49.00 ➝ $91.00
12/10/2020HC WainwrightBoost TargetBuy$53.00 ➝ $64.00
12/4/2020Leerink PartnersBoost TargetOutperform$39.00 ➝ $44.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.31 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 35 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 18 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 16 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 42 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 30 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
10/5/2025
  • 43 very positive mentions
  • 35 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 50 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 50 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

BridgeBio Pharma logo
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $74.76
Low: $72.48
High: $75.04

50 Day Range

MA: $61.54
Low: $50.05
High: $74.76

52 Week Range

Now: $74.76
Low: $25.34
High: $75.04

Volume

1,347,906 shs

Average Volume

2,109,684 shs

Market Capitalization

$14.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of BridgeBio Pharma?

The following Wall Street sell-side analysts have issued research reports on BridgeBio Pharma in the last year: Bank of America Corporation, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Oppenheimer Holdings, Inc., Piper Sandler, Raymond James Financial, Inc., Redburn Atlantic, Scotiabank, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for BBIO.

What is the current price target for BridgeBio Pharma?

0 Wall Street analysts have set twelve-month price targets for BridgeBio Pharma in the last year. Their average twelve-month price target is $74.37, suggesting a possible downside of 0.5%. Cantor Fitzgerald has the highest price target set, predicting BBIO will reach $110.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $49.00 for BridgeBio Pharma in the next year.
View the latest price targets for BBIO.

What is the current consensus analyst rating for BridgeBio Pharma?

BridgeBio Pharma currently has 1 sell rating and 20 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BBIO.

What other companies compete with BridgeBio Pharma?

Other companies that are similar to BridgeBio Pharma include Takeda Pharmaceutical, Insmed, BeOne Medicines, Teva Pharmaceutical Industries and BioNTech. Learn More about companies similar to BridgeBio Pharma.

How do I contact BridgeBio Pharma's investor relations team?

BridgeBio Pharma's physical mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company's listed phone number is (650) 391-9740. The official website for BridgeBio Pharma is bridgebio.com. Learn More about contacing BridgeBio Pharma investor relations.